MALVERN, Pa.--(BUSINESS WIRE)--TetraLogic Pharmaceuticals today announced that the U.S. Patent and Trademark Office issued a third patent with claims that cover birinapant, a Smac mimetic currently in Phase 2 clinical studies for the treatment of various cancers. U.S. patent number 8,283,372 has claims directed specifically to birinapant as a new chemical entity (NCE) and to drug products comprising birinapant. The patent extends TetraLogic’s birinapant patent estate in the United States to June 2030, with potential for extension pursuant to the Hatch-Waxman Act. Counterpart patent applications are pending examination in Europe, Japan, China, and other major and emerging markets.
